The Oncology Research Information Exchange Network (ORIEN), founded by Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCC-James), announced that it has expanded with the addition of four nationally recognized cancer centers.
ORIEN, a research collaboration aimed at improving the understanding of cancer at the molecular level, now includes six US cancer centers in its network. In addition to its anchor members Moffitt and OSUCCC-James, ORIEN has expanded its members to include four new cancer centers, including City of Hope, University of Virginia Cancer Center (UVA), University of Colorado Cancer Center, and University of New Mexico Cancer Center (UNMCC).
The expansion is expected to exponentially increase the number of patients consenting to donate their tissue and clinical data, including corresponding genomic data, for research to understand cancer at the molecular level, in order to develop more targeted cancer drugs.
Additionally, other cancer centers are in the process of joining ORIEN. Those involved in ORIEN share de-identified data to accelerate development of targeted treatments, allowing researchers and clinicians to more quickly match eligible patients to clinical trials and conduct larger and richer analyses. According to Moffitt and OSUCC-James, ORIEN personifies “big data”, with extensive databases with cancer patient information that can be used for basic research and clinical trials, that puts cancer genomics on the leading edge of precision medicine.
“The growth of ORIEN coincides with President Obama’s announcement and the recognition that molecularly targeted medicine holds tremendous promise for all disease, particularly cancer,” said Michael Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute. “We believe ORIEN illustrates a collaborative pathway to operationalize personalized medicine to help discover cures for more patients.”
During his State of the Union address, Obama unveiled the $215 Precision Medicine Initiative. Although precision medicine is new in some fields, it has been used to treat several different types of cancer.
“Rapidly evolving science and modern diagnostics are moving the field of cancer research and cures forward, but it’s not something one institution can accomplish on its own,” said Steven T. Rosen, MD, provost and chief scientific officer for City of Hope and director of the City of Hope Comprehensive Cancer Center. “City of Hope is proud to partner with Moffitt, the OSUCC-James and the new ORIEN members to share data, collaborate and ultimately change the cancer treatment model.”
The cancer centers will adopt Moffitt’s Total Cancer Care protocol, developed in 2006, which creates a standard system for tracking patient molecular, clinical and epidemiological data. Patients that provide their consent are followed throughout their lifetime and agree to be contacted for future studies, playing an active role in the study of their cancer and improving care for future generations.
Source: Moffitt Cancer Center